Mifegyne (Mifepristone)

Mifepristone works by competitively blocking progesterone receptors, which are essential for maintaining the uterine lining during early pregnancy. This antagonism causes decidual breakdown, cervical softening, and detachment of the embryo, facilitating expulsion. In endocrine disorders, it also blocks glucocorticoid receptors, reducing cortisol activity.

The specific dose of Mifegyne is determined by the prescribing clinician based on the indication, gestational age, and local treatment protocols. Typically, a single 200 mg oral tablet is used for early pregnancy termination, but the exact regimen should always follow the prescriber's instructions.

Mifegyne is contraindicated in ongoing pregnancy except when used for its approved indication of medical termination. It should not be used by women who are breastfeeding, as mifepristone can be excreted in breast milk and may affect the infant. Consultation with a healthcare professional is essential.

To order Mifegyne, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

The most common alternative in medical abortion regimens is misoprostol, a prostaglandin analogue that induces uterine contractions. Mifepristone initiates the process by antagonising progesterone, while misoprostol completes it by causing expulsion. Using both sequentially provides higher efficacy than misoprostol alone.

Mifegyne tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Mifegyne is taken orally as a single tablet. The patient should swallow the 200 mg tablet whole with water, following any specific instructions from the prescriber regarding timing relative to other medications such as prostaglandin analogues.

Serious risks include heavy hemorrhage requiring medical intervention, severe infection or sepsis, allergic reactions that may progress to anaphylaxis, and liver dysfunction indicated by elevated enzymes or jaundice. Patients should be monitored closely for these signs and seek immediate medical attention if they occur.

Mifegyne should not be used by individuals with known hypersensitivity to mifepristone, those with chronic adrenal failure, patients on long‑term corticosteroid therapy, women with ectopic pregnancy, or anyone for whom pregnancy exceeds nine weeks gestation. Contraindications also include severe uncontrolled asthma and certain cardiovascular conditions.